Loading...
The shift toward primary human papillomavirus (HPV)–based screening for cervical cancer screening also has shifted our focus toward more comfortable alternatives to speculum-based exams. In 2024, the U.S. FDA approved an in-office, self-collected vaginal swab — and recently has authorized the first at-home option. In two recent studies, researchers compared results of self-collected and clinician-collected specimens and examined uptake of self-collection.
In an industry-sponsored, multisite U.S. study, 582 women self-collected HPV swabs in their physicians' offices, prior to speculum-based clinician sampling. Self-collected samples had >95% agreement with clinician-collected samples for detecting high-risk HPV — thus meeting screening standa…